Revelation Biosciences, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Revelation is a clinical-stage biopharmaceutical company developing immunologic therapeutics and diagnostics. It has not generated revenue and does not expect product revenue for several years, if ever.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $0.53 million | $3.68 million; down $3.16 million |
| General and administrative expense | $1.09 million | $2.91 million; down $1.81 million |
| Total operating expenses / operating loss | $1.62 million | $6.59 million; down $4.97 million |
| Net income (loss) | $6.16 million | $(6.62) million |
| Operating cash flow | $(1.58) million | $(4.83) million |
| Cash and cash equivalents | $17.70 million at March 31 | $5.25 million at December 31, 2022 |
| Total assets / liabilities | $18.12 million / $8.10 million | At March 31, 2023 |
| Stockholders’ equity | $10.02 million | $1.05 million at December 31, 2022 |
Q1 net income was driven by a $7.74 million non-cash gain from a decrease in the fair value of liability-classified Class C warrants, not by operating revenue. Excluding that warrant gain, operations remained loss-making. The filing does not present a meaningful gross margin because the company had no revenue. Financing provided $14.02 million, primarily net proceeds from the February 2023 offering. No conventional borrowing debt is reported at quarter-end; current liabilities include a $3.51 million warrant liability and $2.91 million in deferred underwriting commissions.
Material changes and capital structure
- Operating expenses fell substantially year over year. R&D expense declined mainly because Q1 2022 included REVTx-99a clinical study costs; G&A declined mainly due to lower advisory, legal, consulting, insurance, and personnel costs.
- The February 2023 public offering raised $14.0 million net and included 2,888,600 common shares, pre-funded warrants, and Class C common stock warrants. The outstanding common-share count rose from 682,882 at December 31, 2022 to 4,729,839 at March 31, 2023.
- The company effected a 1-for-35 reverse stock split on February 1, 2023 and increased authorized common shares from 100 million to 500 million. It regained Nasdaq minimum bid-price and stockholders’ equity compliance in February.
- During Q1, holders exercised Class C warrants through alternative cashless exercises, resulting in 965,357 shares issued. Further exercises after quarter-end left 1,108,260 Class C warrants outstanding as of May 16, 2023.
Outlook, liquidity, risks, and contingencies
- Going concern: Management states the $17.7 million cash balance is not expected to sustain operations for one year after issuance of the financial statements, raising substantial doubt about the company’s ability to continue as a going concern. Additional capital is required; financing may be unavailable or dilutive, and failure to raise funds could delay, reduce, or eliminate development programs.
- Management expects significant operating losses and negative operating cash flows for the foreseeable future, and expects R&D spending to increase as programs advance. Timing, cost, regulatory approval, and eventual revenue remain uncertain.
- Legal matters: LifeSci Capital seeks approximately $2.7 million cash and $2.6 million in equity for disputed advisory fees. Separately, an IPO underwriter demanded $655,000 in fees; together with $1.5 million of the LifeSci claim, amounts are included in deferred underwriting commissions. A-IR Clinical Research seeks £1.6 million plus interest and costs over disputed viral-challenge-study invoices. The company disputes both claims; no additional liability is recorded where the amount cannot be determined.
- The company has an operating lease for laboratory space through December 31, 2023, with $86,670 in remaining minimum payments. It reports no off-balance-sheet arrangements and no material changes to previously disclosed risk factors.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2023; no material change in internal control over financial reporting was reported.
Key investor verification points
- Assess the going-concern warning against cash burn, expected R&D investment, and the company’s ability to raise additional capital.
- Separate operating performance from the $7.74 million non-cash warrant revaluation gain when evaluating reported net income.
- Review dilution and potential share issuance from the February offering, remaining warrants, and any future financing.
- Track the status and potential financial exposure of the LifeSci and A-IR disputes, including the separate $655,000 underwriter demand.
- Verify development progress, funding needs, and regulatory timelines for REVTx-300, REVTx-100, REVTx-200, REVTx-99b, and REVDx-501; the filing provides no revenue guidance.